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Abstract: We present a new near infrared optical probe for the sentinel 
lymph node detection, based on the recording of scattered photons. A two 
wavelengths setup was developed to improve the detection threshold of an 
injected  dye:  the  Patent  Blue  V  dye.  The  method  used  consists  in 
modulating each laser diode at a given frequency. A Fast Fourier Transform 
of the recorded signal separates both components. The signal amplitudes are 
used to compute relative Patent Blue V concentration. Results on the probe 
using  phantoms  model  and  small  animal  experimentation  exhibit  a 
sensitivity threshold of 3.2 µmol/L, which is thirty fold better than the eye 
visible threshold. 
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1. Introduction 
The  lymphatic  system  includes  three  distinct  subsets:  the  lymphatic  capillaries,  lymphatic 
vessels and thoracic duct. Lymph is drained from the lymphatic capillaries to the lymph nodes 
where it penetrates to be filtered. The sentinel lymph node is defined as the first node that 
receives afferent lymphatic drainage from a tumour. These nodes have a spheroid shape with 
dimensions varying from 1 to 15 mm. 
In  1960,  E.A.  Gould  was  the  first  to  introduce  the  sentinel  lymph  node  concept  [1]. 
According to him, a tumour is drained preferentially in the direction of the first node risking a 
metastatic  invasion.  If  this  latter,  called  also  sentinel  lymph  node  is  not  invaded,  all  the 
axillary lymph nodes are negative. Indeed, its histological status is representative of the status 
of the other nodes of the chain [2]. The axillary chain is the most involved lymphatic chains 
(85%)  in  the  lymph  drainage  of  the  breast.  Thus,  for  breast  cancer,  when  the  tumor  is 
invasive, the first approach  consists in removing the entire lymph  node from the axillary 
chain.  An other procedure used in clinical routine is clearly defined as  the sentinel  node 
method: a lymphophilic tracer (radio-isotope [3] or/and dye [4]) is injected in the vicinity of 
the tumour or in the periareolar area [5]. A first detection of the sentinel node is determined 
percutaneously,  usually  with  a  nuclear  probe.  A  second  detection,  carried  out  after  skin 
incision in the armpit, involves both nuclear and optical (visual) analysis. Studies have shown 
that  the  sentinel  node  method  is  associated  with  less  morbidity  compared  to  the  axillary 
dissection [6]. 
Detection  of  sentinel  lymph  node  using  other  optical  methods  has  been  recently 
developed. One of them is a self-assembled complex of radiocolloid (
99mTc) with fluorescent 
agent: the indocyanine green (ICG) for combined pre-and intraoperative imaging of sentinel 
lymph nodes [7,8]. Other techniques are now under development such as photoacoustic or 
fluorescence detection. On one  hand,  many studies propose the photoacousic approach to 
detect  sentinel  lymph  nodes  using  tracers  like  nanorods  [9]  or  nanobeacons  [10].  These 
methods are promising but their applications in humans are still experimental. On the other 
hand, studies using fluorescent tracers on animal model have permitted the detection and the 
imaging of lymph node [11–13]. Moreover, the use of indocyanine green (ICG) has recently 
yielded the first imaging of  lymphatic system of  human  and performed to investigate the 
clinical feasibility of ICG fluorescence imaging [14,15]. 
We propose an alternative based on a very simple optical device to detect and identify 
sentinel lymph nodes. This can be achieved through a colorimetric procedure using a dye. 
Patent Blue V [16] is the most frequently used dye in clinical routine. To detect the blue nodes 
surgeons  usually  rely  on  visual  inspection.  The  use  of  the  Patent  Blue  V  dye  for  this 
experiment is a considerable asset for future clinical application. We designed an easy used 
probe, based on two laser diodes and a photodiode detector, to detect automatically the dye. 
We have demonstrated that the probe has a better sensitivity then the visual appreciation of 
the surgeon. Two experimental cases were developed to highlight the advantages of the probe: 
phantoms and small animal experimentation. 
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When a wave propagates in an absorbing and scattering medium, the decrease in intensity, IT, 
can  be  expressed  using  the  modified  Beer-Lambert  law.  In  the  following  expressions, 
absorption by the Patent Blue V dye is discriminated from absorption by other chromophores 
present in the phantom/tissue under study. The backscattered light intensity detected by the 
detector can be written as: 
 
( ) .
0.
aPB aT µ l
T I I e
  β − + =    (1) 
where I0 is the intensity of light backscattered by a non absorbing sample, µaT the optical 
absorption coefficient of tissue, µaPB the optical absorption of the Patent Blue V, l the distance 
between the light source and detector and β the differential pathlenght factor which depends 
on  the  scattering  and  absorption  optical  properties  of  the  medium.  With 
2.3. . aPB PB PB µ C ε = where CPB is the dye concentration εPB is the molar extinction coefficient of 
the Patent Blue V dye 
In  a  first  step,  when  the  absorption  changes  remain  small  as  compared  to  the  initial 
absorption,  the  product  l.β  is  assumed  to  be  constant  during  the  experiment.  When  this 
approximation does not hold, a more complex model should be considered. In such cases, we 
used  the  one  described  by  Contini  and  al  [17],  derived  from  the  Patterson  model,  which 
express I as a function of the optical absorption and scattering properties of a homogeneous, 
semi-infinite medium: 
 
1 2 1 2
0
. .
. 1 exp
PB PB aT PB PB aT
T
C C
I I l l
D D
ε   ε       + +     = + −        
           
   (2) 
where D is the diffusion coefficient, 
' 1 3 s D µ = ,µ’s the reduced scattering coefficient. 
Equation (1) shows that, if the tissue absorption coefficient is constant, variations in the 
backscattered signal can only be due to changes in Patent Blue V concentration. This can be 
monitored with a single-wavelength setup. If µaT varies during the detection process, either as 
a result of time variations or changes in the position of the probe, the two parameters µaPB and 
µaT should be measured separately, which requires at least a two-wavelength setup. 
To determine the Patent Blue V concentration, we used the Eq. (1), with an added term ID 
to take into account for dark correction. ID is measured without scattered signal: 
 
( ) .
0.
aPB aT µ µ l
T D I I e I
β − + = +    (3) 
After an initial measurement on a non absorbing sample,  0 0 T D I I I = + , it is possible to 
compute the product of the total absorption coefficient times l.β: 
  ( )
0 . ln
T D
aPB aT
T D
I I
R µ µ l
I I
β
  −
= + =   −  
   (4) 
If the initial measurement is performed on a sample without dye, we can express it as 
  ( ) 0 .
0 0
aT µ l
T D I I e I
β −
= +    (5) 
We can compute the sum of the absorption by the dye µaPB and the variation of absorption 
by tissues 
0 aT aT aT µ µ µ   = − : 
  ( )
0 . ln
T D
aPB aT
T D
I I
R µ µ l
I I
β
  −
= +  =   −  
   (6) 
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Blue V concentration by solving a system of two linear equations with two unknowns. This 
linear system can be written as follow: 
  . Y A X =    (7) 
where 
1
2
R
Y
R
 
=  
 
,
11 12
21 22
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ε ε
ε ε
 
=  
 
 the molar extinction coefficients matrix with εij representing 
the molar absorption of chromophore (dye or tissue) i at the wavelength j and 
1
2
. .
C
X l
C
β
 
=  
 
 
the computed vector of concentrations multiplied by β.l. The concentrations are  1 PB C C = the 
dye concentration and  2 C  an expression of the tissue chromophores concentrations, according 
to the definition of their molar extinction coefficients. 
3. Material and methods 
3.1. Probe 
The instrument is based on two laser diodes (LDM modules, ILEE) and a photodiode (S5106, 
HAMAMATSU). Both lasers are controlled via a National Instrument (NI USB-6008 OEM) 
card connected to a computer via a USB port. The signal from the photodiode is digitalized by 
the same card with a sampling frequency equal to 1000 Hz. The explored area is illuminated 
with a probe pen which includes the 2 optical fibers for emission and the receiving fiber, 
positioned as a triangle. Emission and reception fibers are 4 mm apart (Fig. 1). 
The absorption spectrum of Patent Blue V exhibits maximum absorption at 638 nm. We 
implemented the first laser beam with a wavelength near to this maximum (657 nm), and, in 
order to detect optical absorption by tissues the second beam with a wavelength not absorbed 
by the dye (785 nm). The method used consists in modulating each laser diode at a given 
frequency, 15 Hz and 25 Hz for the laser diodes at 657 nm and 785 nm, respectively. A Fast 
Fourier  Transform  of  the  recorded  signal  separates  both  components.  It  also  allows 
distinguishing  them  from  the  ambient  light  detected.  The  signal  amplitudes  at  both 
wavelengths are then used to compute the relative values of the Patent Blue V concentration, 
as described in the above section. 
Laser 1 (657nm)
Laser 2 (785nm)
Photodiode Laptop 
computer
Acquisition 
card Probe 
pen
 
Fig. 1. Schematic diagram of the setup. 
3.2. Phantoms description 
Preliminary studies were carried out on 1% Intralipid solutions to which Black India ink was 
added  to  simulate  absorption  and  scattering  by  breast  tissues  [18].  We  choose  a  reduced 
scattering coefficient µ’s equal to 0.89 mm
−1 [19] and an absorption coefficient  a equal to 
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−1 at 650 nm. Patent Blue V (Bleu Patente V Sodique, Guerbet) was finally added by 
successive injections. 
3.3. Small animal experimentation 
In order to detect lymph nodes in vivo we have used an animal model with active nodes in a 
myelin basic protein (MBP) induced acute Experimental Allergic Encephalomyelitis (EAE) 
model of Lewis rat [20]. 
The emulsion was composed of a mixture of equal volumes of two solutions prepared 
separately: the complete Freund’s adjuvant (CFA) and the antigen solution. The complete 
Freund’s  adjuvant  was  prepared  from  4mg  of  Mycobacterium  tuberculosis  strain  H37RA 
(Difco) per milliliter of incomplete Freund’s adjuvant (Sigma F5506). The antigen solution 
was prepared from MBP at 2mg/ml in phosphate buffered saline (PBS). 
Rats were anesthetized with an intramuscular injection containing 100mg/kg of ketamine 
and  10mg.kg  of  xylazine  and  were  inoculated  subcutaneously  in  the  hind  limbs  with  the 
mixture of MBP/CFA. 
Ten days after the injection of the mixture MBP/CFA we had made, after anesthesia of rat 
with isoflurane, the detection of lymph nodes. Patent Blue V was injected intradermically in 
the hind limbs. The dye was drained preferentially to the inguineal node, the popliteal node 
and  the  iliac  node  [21].  The  rat  was  controlled  during  the  experiment  with  a  system  of 
anesthesia and temperature control (MINERVE). 
Two types of experiments had done. The first consisted in placing the probe on the skin, 
facing the selected node: inguinal node. We injected the Patent Blue V dye in the limbs and 
we recorded the signals during about 25 minutes. Several volumes were injected from 15µl to 
50µL. During the second, the probe is moved to detect different nodes through the skin and 
fur. 
4. Results 
4.1. Phantom study results 
The results presented on Fig. 2 correspond to the amplitude variations of backscattered signals 
at  657nm  and  785nm  during  successive  injections  of  Patent  Blue  V.  When  the  dye 
concentration increases, we observe a rapid decrease of the signal intensity at 657nm. This 
result  fulfills  the  modified  Beer-Lambert  law  (blue  plot).  In  this  case  we  cannot  see  a 
significant difference with the Patterson model (red plot). Moreover, the intensity of the signal 
at 785nm remains relatively constant. The slight increase can be due to the gradual diluting in 
the solution. The vertical straight line at 1 µmol/L corresponds to the visibility threshold of 
the dye by the experimenters. 
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Fig. 2. Backscattered signals at 657 and 785 nm recorded during successive injections of Patent 
Blue V: experimental results and data fitted using the Beer Lambert law and the Patterson 
model. 
To demonstrate the relevance of the Patterson model, another experiment is illustrated in 
the Fig. 3. This experiment consists to successive injections of Black Ink India in a solution of 
intralipid. In this graph we observe variations of the signal at 785nm. We fit our data with the 
modified  Beer-Lambert  law  and  the  Patterson  law.  Both  fitting  curves  were  close  to  the 
experimental data but the modified Patterson model is more appropriate. Indeed, the residual 
error is four times lower, and the Patterson model takes into changes in the mean pathlength 
of light as the absorption increases. 
 
Fig. 3. Comparison of the modified Beer-Lambert law and Patterson model applied on data 
recorded for different concentrations of black India Ink. 
Two  methods  were  used  to  determine  the  detection  threshold  of  the  probe.  The  first 
consisted  in  determining  graphically  the  first  value  outside  the  noise  of  the  initial 
measurement [Fig. 4(a)]; the second is a graphical plot of ROC curve (Receiver Operating 
Characteristic) [22]: sensitivity (Se) versus 1- specificity (Sp). The groups of experiments 
correspond to the number of acquisitions performed in a time series for a given concentration 
dye. Solution without Patent Blue V dye was used as a reference group, and compared to the 
other groups obtained after dye injections. We can fully discriminate the third group from the 
first [Fig. 4(b)] despite of the presence of outliers. With both methods, the detection threshold 
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−2 µmol/L. The eye visible threshold was estimated at 
about 1 µmol/L (Fig. 2). 
We  have  also  considered  variations  in  signal  amplitude  recorded  with  a  fix  probe  at 
different distances from the Intralipid surface. Artifacts come from the reflected light on the 
sample surface. They can shad the detection, but we demonstrated that the design of the probe 
allow a significant detection up to a distance of 7 mm. 
 
Fig. 4. Determination of the detection threshold: a. comparison of successive amplitude of the 
backscattered signal, b. ROC curve analysis. 
4.2. Animal experimentation results 
Five Lewis rats were inoculated twice with a mixture MPB/CFA (100µL per limb) under 
anesthesia. After the first injection, all animals have developed acute EAE with inflammation 
nodes according to with the model [10]. The evolution of weights and clinical signs were 
correlated with the expectation on this model. Subsequently to the second inoculation, four 
rats have developed inflammation without apparent clinical signs. Indeed, after palpation we 
were able to note swollen inflamed nodes sizing about 5 mm. 
Two types of measurements were carried out on the four rats bearing inflamed nodes. For 
each  the  results  are  represented  graphically.  The  red  curve  represents  the  amplitude’s 
variations at 785nm, the green curves represent the variations of 650nm signal and the blue 
curves  represents  the  variations  of  Patent  Blue  concentration  multiplied  by  the  β  factor 
computed from Eqs. (6) and (7) with the extinction coefficients of tissues corresponding to 
blood with a saturation coefficient of hemoglobin in oxygen equal to 90%. 
 
Fig.  5.  Time  variations  of  the  signals  at  657  nm  and  785  nm  and  computed  relative 
concentration of dye. Patent Blue V volume injection = 50µL. 
We propose in the Fig. 5 an example of result for Patent Blue V injected volume of 50µL. 
We observe the decrease of the intensity of the signal at 657nm thus the intensity of the signal 
at 785nm, which is not absorbed by the dye, staying constant during the experiment. The blue 
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outliers on recorded data at 657nm and 785nm can be interpreted as respiratory movement 
artifacts. 
The second kind of experiment is shown in Fig. 6. After an injection of 50µL of Patent 
Blue V, which is not visible by eye through the fur of the animal, the probe is moved to detect 
different nodes through the skin and fur. 
During the first minute, the probe was on the skin but not facing a node. In this case, the 
computed value of the Patent Blue V concentration is close to zero. When the probe is moved 
upon the inguinal node, the accumulation of the dye in this node is illustrated from minute 1 
to 2, by the decrease of the amplitude signal at 657nm, the relatively constant amplitude signal 
at 785nm and the computed value of Patent Blue V concentration (times β) increases to a 
value of 10µmol/L. The probe is then moved on the iliac node during the second minute and 
the popliteal node during the third. 
 
Fig. 6. Research of nodes: computed Patent Blue V concentration times β for different positions 
of the probe. 
The results show the variations of amplitude signal at 657nm in each case the amplitude 
signal  at  785nm  was  relatively  constant  during  all  the  experiment.  This  experiment  has 
allowed us the determination of dye distribution in different nodes. Indeed, we were able to 
observe three distinct parts on the blue curve representing the three computed concentrations 
of the dye for three positions of the probe facing nodes. 
5. Conclusion and prospects 
The developed instrument presents the advantage of working  with the Patent Blue V dye 
which is already used in clinical routine. Herein, we have demonstrated that the probe allows 
the detection of the dye at ambient light, both in a phantom model and in a small animal 
model. The phantom model allows us to determine the detection threshold of the probe. The 
probe in contact with the sample was able to detect concentration of blue as low as 3.2 10
−2 
µmol/L. During the animal experimentation, the probe has detected the dye accumulation and 
fixation on different nodes for a very few volume of Patent Blue dye (15µL) through the skin 
and  the  fur.  Additionally,  on  the  economic  aspect,  the  instrumentation  and  the  dye  are 
available at reasonable cost. 
This  probe  also  demonstrates  disadvantages  such  as  the  absence  of  quantification  in 
heterogeneous  medium,  due  to  the  use  of  the  Beer-Lambert  law,  and  the  limited  depth 
resolution. To solve these problems, the 4mm separation between the source and the detector 
can be modified if more depth penetration is needed and power of lasers can be adapted. 
Moreover,  the  use  of  diffuse  optical  tomography  (DOT)  could  be  an  alternative  to  our 
approach since it should result both in an increase of depth detection and in an improvement 
of  spatial  resolution.  However,  this  technique  is  hardly  compatible  with  intraoperative 
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development in our lab. 
Following these results, a study has begun to test our probe in clinical environment. The 
medical probe based on this new technique allows helping the surgeon diagnostic during the 
node excision and to detect non eye visible blue node and thus, significantly reduce false 
negatives. The first measurements in ex vivo conditions, on axillary dissection or zonectomy, 
has given interesting results but also showed the limit of this very simple device. 
In fact, this probe does not completely account the biological tissues absorption, especially 
absorption  due  to  haemoglobin.  Indeed,  the  two  forms  of  haemoglobin  (oxy  and  deoxy-
haemoglobin)  have  a  clearly  different  molar  absorption  coefficients  at  657nm.  At  this 
wavelength, the absorption of the deoxy-haemoglobin is higher that the oxy-haemoglobin. 
Thus a decrease in blood oxygenation will result in an increase of the absorption at 657nm 
and  will be interpreted by the probe as an  increase of  dye concentration. To correct this 
problem,  a  second  probe,  with  four  wavelengths,  is  being  developed,  based  on  the  same 
physical principle. It will measure dye concentration taking into account the blood oxygen 
saturation 
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